NASDAQ:FWAA

Fifth Wall Acquisition Corp. I Competitors

Notice: Trading of Fifth Wall Acquisition Corp. I halted at 07:55 AM EST due to "News pending".

$10.23

0.00 (0.00 %)

(As of 04/21/2021 12:00 AM ET)

Add

Compare

Today's Range

$10.09

Now: $10.23▼

$10.26

50-Day Range

$9.94

MA: $10.23▼

$10.80

52-Week Range

$9.77

Now: $10.23▼

$11.67

Volume17,459 shs

Average Volume194,525 shs

Market Capitalization$393.43 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Fifth Wall Acquisition Corp. I (NASDAQ:FWAA) Vs. APR, DSGN, TBA, BVS, ADAG, and IKNA

Should you be buying FWAA stock or one of its competitors? Companies in the industry of "--" are considered alternatives and competitors to Fifth Wall Acquisition Corp. I, including Apria (APR), Design Therapeutics (DSGN), Thoma Bravo Advantage (TBA), Bioventus (BVS), Adagene (ADAG), and Ikena Oncology (IKNA).

Fifth Wall Acquisition Corp. I vs. Apria Stock

Fifth Wall Acquisition Corp. I (NASDAQ:FWAA) and Apria (NYSE:APR) are both small-cap -- companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.

Profitability

This table compares Fifth Wall Acquisition Corp. I and Apria's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fifth Wall Acquisition Corp. I	N/A	N/A	N/A
Apria	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings for Fifth Wall Acquisition Corp. I and Apria, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fifth Wall Acquisition Corp. I	0	0	0	0	N/A
Apria	0	0	5	0	3.00

Apria has a consensus price target of $29.20, indicating a potential downside of 3.73%. Given Apria's higher probable upside, analysts plainly believe Apria is more favorable than Fifth Wall Acquisition Corp. I.

Valuation and Earnings

This table compares Fifth Wall Acquisition Corp. I and Apria's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fifth Wall Acquisition Corp. I	N/A	N/A	N/A	N/A	N/A
Apria	N/A	N/A	N/A	N/A	N/A

Summary

Apria beats Fifth Wall Acquisition Corp. I on 2 of the 2 factors compared between the two stocks.

Fifth Wall Acquisition Corp. I vs. Design Therapeutics Stock

Fifth Wall Acquisition Corp. I (NASDAQ:FWAA) and Design Therapeutics (NASDAQ:DSGN) are both small-cap -- companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.

Valuation and Earnings

This table compares Fifth Wall Acquisition Corp. I and Design Therapeutics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fifth Wall Acquisition Corp. I	N/A	N/A	N/A	N/A	N/A
Design Therapeutics	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings for Fifth Wall Acquisition Corp. I and Design Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fifth Wall Acquisition Corp. I	0	0	0	0	N/A
Design Therapeutics	0	1	2	0	2.67

Design Therapeutics has a consensus price target of $35.3333, indicating a potential upside of 80.73%. Given Design Therapeutics' higher probable upside, analysts plainly believe Design Therapeutics is more favorable than Fifth Wall Acquisition Corp. I.

Profitability

This table compares Fifth Wall Acquisition Corp. I and Design Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fifth Wall Acquisition Corp. I	N/A	N/A	N/A
Design Therapeutics	N/A	N/A	N/A

Summary

Design Therapeutics beats Fifth Wall Acquisition Corp. I on 2 of the 2 factors compared between the two stocks.

Fifth Wall Acquisition Corp. I vs. Thoma Bravo Advantage Stock

Thoma Bravo Advantage (NYSE:TBA) and Fifth Wall Acquisition Corp. I (NASDAQ:FWAA) are both small-cap -- companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.

Profitability

This table compares Thoma Bravo Advantage and Fifth Wall Acquisition Corp. I's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Thoma Bravo Advantage	N/A	N/A	N/A
Fifth Wall Acquisition Corp. I	N/A	N/A	N/A

Earnings & Valuation

This table compares Thoma Bravo Advantage and Fifth Wall Acquisition Corp. I's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Thoma Bravo Advantage	N/A	N/A	N/A	N/A	N/A
Fifth Wall Acquisition Corp. I	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for Thoma Bravo Advantage and Fifth Wall Acquisition Corp. I, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Thoma Bravo Advantage	0	0	0	0	N/A
Fifth Wall Acquisition Corp. I	0	0	0	0	N/A

Fifth Wall Acquisition Corp. I vs. Bioventus Stock

Bioventus (NYSE:BVS) and Fifth Wall Acquisition Corp. I (NASDAQ:FWAA) are both small-cap -- companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, profitability, valuation and earnings.

Earnings and Valuation

This table compares Bioventus and Fifth Wall Acquisition Corp. I's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	N/A	N/A	N/A	N/A	N/A
Fifth Wall Acquisition Corp. I	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Bioventus and Fifth Wall Acquisition Corp. I's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioventus	N/A	N/A	N/A
Fifth Wall Acquisition Corp. I	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Bioventus and Fifth Wall Acquisition Corp. I, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0	0	4	0	3.00
Fifth Wall Acquisition Corp. I	0	0	0	0	N/A

Bioventus currently has a consensus target price of $19.50, indicating a potential upside of 32.29%. Given Bioventus' higher possible upside, research analysts plainly believe Bioventus is more favorable than Fifth Wall Acquisition Corp. I.

Summary

Bioventus beats Fifth Wall Acquisition Corp. I on 2 of the 2 factors compared between the two stocks.

Fifth Wall Acquisition Corp. I vs. Adagene Stock

Fifth Wall Acquisition Corp. I (NASDAQ:FWAA) and Adagene (NASDAQ:ADAG) are both small-cap -- companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Profitability

This table compares Fifth Wall Acquisition Corp. I and Adagene's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fifth Wall Acquisition Corp. I	N/A	N/A	N/A
Adagene	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings and recommmendations for Fifth Wall Acquisition Corp. I and Adagene, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fifth Wall Acquisition Corp. I	0	0	0	0	N/A
Adagene	0	0	3	0	3.00

Adagene has a consensus target price of $32.00, suggesting a potential upside of 107.79%. Given Adagene's higher probable upside, analysts plainly believe Adagene is more favorable than Fifth Wall Acquisition Corp. I.

Valuation & Earnings

This table compares Fifth Wall Acquisition Corp. I and Adagene's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fifth Wall Acquisition Corp. I	N/A	N/A	N/A	N/A	N/A
Adagene	N/A	N/A	N/A	N/A	N/A

Summary

Adagene beats Fifth Wall Acquisition Corp. I on 2 of the 2 factors compared between the two stocks.

Fifth Wall Acquisition Corp. I vs. Ikena Oncology Stock

Ikena Oncology (NASDAQ:IKNA) and Fifth Wall Acquisition Corp. I (NASDAQ:FWAA) are both small-cap -- companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Profitability

This table compares Ikena Oncology and Fifth Wall Acquisition Corp. I's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ikena Oncology	N/A	N/A	N/A
Fifth Wall Acquisition Corp. I	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations for Ikena Oncology and Fifth Wall Acquisition Corp. I, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ikena Oncology	0	0	3	0	3.00
Fifth Wall Acquisition Corp. I	0	0	0	0	N/A

Ikena Oncology presently has a consensus target price of $30.00, suggesting a potential upside of 55.93%. Given Ikena Oncology's higher probable upside, research analysts clearly believe Ikena Oncology is more favorable than Fifth Wall Acquisition Corp. I.

Valuation and Earnings

This table compares Ikena Oncology and Fifth Wall Acquisition Corp. I's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ikena Oncology	N/A	N/A	N/A	N/A	N/A
Fifth Wall Acquisition Corp. I	N/A	N/A	N/A	N/A	N/A

Summary

Ikena Oncology beats Fifth Wall Acquisition Corp. I on 2 of the 2 factors compared between the two stocks.